Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies
BMJ 360:k1717, Adderley, N.J.,et al, 2018
Diagnosis and Management of Active Intracranial Atherosclerotic Disease
Stroke 49:e221-e223, Narwal, P.,et al, 2018
Ischemic Stroke in Cancer Patients: A Review of an Underappreciated Pathology
Ann Neurol 83:873-883, Navi, B.B. & Iadecola, C., 2018
Pregnancy, Hormonal Treatments for Infertility, Contraception, and Menopause in Women After Ischemic Stroke
Stroke 48:501-506, Caso, V.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Effects of Aspiring on Risk and Severity of Early Recurrent Stroke After Transient Ischaemic Attack and Ischaemic Stroke: Time-Course Analysis of Randomised Trials
Lancet: 388:365-375, 312, Rothwell, P.M.,et al, 2016
Antiplatelet Treatment Compared with Anticoagulation Treatment for Cervical Artery Dissection (CADISS): A Randomized Trial
Lancet Neurol 14:361-367, the CADISS Trial investigators, 2015
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Effects of Clopidogrel Added to Aspirin in Patients with Recent Lacunar Stroke
NEJM 367:817-825, The SPS3 Investigators, 2012
Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurence
Stroke 42:2509-2514, Broderick, J.,et al, 2011
Population-Based Study of Behavior Immediately After Transient Ischemic Attack and Minor Stroke in 1000 Consecutive Patients: Lessons for Public Education
Stroke 41:1108-1114, Chandratheva,A.,et al, 2010
Effect of Combined Aspirin and Extended-Release Dipyridamole Versus Clopidogrel on Functional Outcome and Recurrence in Acute, Mild Ischemic Stroke: PRoFESS Subgroup Analysis
Stroke 41:732-738, Bath,P.M.W., et al, 2010
Urgency of Carotid Endarterectomy for Secondary Stroke Prevention: Results from the Registry of the Canadian Stroke Network
Stroke 40:2776-2782, Gladstone,D.J.,et al, 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
EXPRESS Transient Ischemic Attack Study: Speed the Process!
Stroke 39:2400-2401, Amarenco,P. &Benavente,O., 2008
Aspirin and Extended-Release Dipyridamole Versus Clopidogrel for Recurrent Stroke
NEJM 359:1238-1251,1287, Sacco,R.L.,et al, 2008
Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study
Stroke 38:1881-1885,1736, Hackam,D.D. &Spence,J.D., 2007
Effect of Urgent Treatment of Transient Ischaemic Attack and Minor Stroke on Early Recurrent Stroke (EXPRESS Study): A Prospective Population-Baed Sequential Comparison
Lancet 370:1432-1442,1398, Rothwell,P.M., et al, 2007
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: No
Stroke 35:804-805,806, Tong,D.C. &Becker,K.J., 2004
Patent Foramen Ovale and Recurrent Stroke: Closure is the Best Option: Yes
Stroke 35:803-804,806, Furlan,A.J., 2004
Emergent Use of Anticoagulation for Treatment of Patients with Ischemic Stroke
Stroke 33:856-861, Adams,H.P., 2002
Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial
Stroke 33:1723-1726, Hankey,G.J., 2002
Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke
Neurol 59:13-22, Coull,B.M.,et al, 2002
Suppression of Recurrent Transient Ischemic Attacks by a Statin Agent
Neurol 56:531-532, Alberts,M.J., 2001
Randomised Trial of a Perindopril-based Blood-pressure-lowering Regimen Among 6105 Individuals with Previous Stroke or Transient Ischaemic Attack
Lancet 358:1033-1041,1026, PROGRESS Collaborative Group, 2001
A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke
NEJM 345:1444-1451,1493, Mohr,J.P.,et al, 2001
Stroke Prevention
Neurol Clin 18:321-341, Wein,T.H. &Bornstein,N.M., 2000
Mobile Aortic Atheroma & Systemic Emboli:Efficacy of Anticoag & Influence of Plaque Morphol on Recurr Stroke
J Am Coll Cardiol 31:134-138, Dressler,F.A.,et al, 1998
Warfarin Use Following Ischemic Stroke Among Medicare Patients with Atrial Fibrillation
Arch Int Med 158:2093-2100, Brass,L.A.,et al, 1998
Preventing Stroke Recurrence in Patients with Patent Foramen Ovale: Antithrombotic Therapy, Foramen Closure, or Therapeutic Abstention? A Decision Analytic Perspective
Am Heart J 135:532-541, Nendaz,M.R.,et al, 1998
Risk of Recurrent Stroke in Patients with Sickle Cell Disease Treated with Erythrocyte Transfusions
J Pediatr 126:896-899, Pegelow,C.H.,et al, 1995
Patent Foramen Ovale and Brain Infarct:Echocardiographic Predictors, Recurrence, and Prevention
Stroke 25:782-786, Hanna,J.P.,et al, 1994
Secondary Prevention of Stroke
Lancet 339:724-727, Warlow,C., 1992
Ticlopidine vs Aspirin for Prevention of Recurrent Stroke, Analysis of Pts with Stroke from Ticlopidine Aspirin Study
Stroke 23:1723-1727, Harbison,J.W., 1992
Frequency, Etiology, and Prevention of Stroke in Patients with Systemic Lupus Erythematosus
Stroke 20:583-591, Futrell,N.&Millikan,C., 1989
High-Dose Acetylsalicylic Acid after Cerebral Infarction
A Swedish Cooperative Study, Stroke 18:325-3341987., , 1987
Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting:A Scientific Statement From the American HEart Association
Stroke 54:e109-e121, Hardik,P.A.,et al, 2023
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020